{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:42:03Z","timestamp":1790516523065,"version":"4.1.0"},"reference-count":159,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1016\/j.clinthera.2005.09.010","type":"journal-article","created":{"date-parts":[[2005,11,13]],"date-time":"2005-11-13T12:12:02Z","timestamp":1131883922000},"page":"1343-1382","source":"Crossref","is-referenced-by-count":123,"title":["Pemetrexed: A multitargeted antifolate"],"prefix":"10.1016","volume":"27","author":[{"given":"Kristan D.","family":"Rollins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Lindley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2005.09.010_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JCO.1993.11.1.5","article-title":"Karnofsky memorial lecture. Ode to methotrexate","volume":"11","author":"Bertino","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib2","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/jn\/129.4.779","article-title":"Folate metabolism and requirements","volume":"129","author":"Bailey","year":"1999","journal-title":"J Nutr"},{"key":"10.1016\/j.clinthera.2005.09.010_bib3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0163-7258(85)90083-X","article-title":"The cellular pharmacology of methotrexate","volume":"28","author":"Goldman","year":"1985","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2005.09.010_bib4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1997.15.1.389","article-title":"Thymidylate synthase inhibitors in cancer therapy: Direct and indirect inhibitors","volume":"15","author":"Rustum","year":"1997","journal-title":"J Clin Oncol"},{"issue":"Suppl 6","key":"10.1016\/j.clinthera.2005.09.010_bib5","first-page":"3","article-title":"An overview of folate metabolism: Features relevant to the action and toxicities of antifolate anticancer agents","volume":"26","author":"Calvert","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib6","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1021\/jm00101a023","article-title":"A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidine synthase","volume":"35","author":"Taylor","year":"1992","journal-title":"J Med Chem"},{"key":"10.1016\/j.clinthera.2005.09.010_bib7","first-page":"1116","article-title":"LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes","volume":"57","author":"Shih","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2005.09.010_bib8","series-title":"Alima (pemetrexed) [product information]","year":"2004"},{"key":"10.1016\/j.clinthera.2005.09.010_bib11","first-page":"459","article-title":"Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: Correlates of molecular-structure and biological activity","volume":"48","author":"Westerhof","year":"1995","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib12","first-page":"3687","article-title":"The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate","volume":"6","author":"Zhao","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2005.09.010_bib13","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1158\/1078-0432.CCR-03-0157","article-title":"The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs","volume":"10","author":"Theti","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2005.09.010_bib14","doi-asserted-by":"crossref","first-page":"6256","DOI":"10.1158\/1078-0432.CCR-04-0645","article-title":"Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier","volume":"10","author":"Wang","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2005.09.010_bib15","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0006-2952(97)00673-4","article-title":"Characterization of folate transport mediated by a low pH route in mouse L1210 leukemia cells with defective reduced folate carrier function","volume":"55","author":"Sierra","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib16","first-page":"326","article-title":"Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs","volume":"48","author":"Habeck","year":"1995","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib17","first-page":"437","article-title":"Role of thymidylate synthase in the antitumor activity of the multi-targeted antifolate, LY231514","volume":"19","author":"Schultz","year":"1999","journal-title":"Anticancer Res"},{"issue":"Suppl 18","key":"10.1016\/j.clinthera.2005.09.010_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/sonc.2002.37461","article-title":"Molecular, biochemical, and cellular pharmacology of pemetrexed","volume":"29","author":"Goldman","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib19","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1634\/theoncologist.9-3-242","article-title":"Enter Alimta: A new generation antifolate","volume":"9","author":"Zhao","year":"2004","journal-title":"Oncologist"},{"issue":"Suppl 6","key":"10.1016\/j.clinthera.2005.09.010_bib20","first-page":"63","article-title":"Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines","volume":"26","author":"Smith","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib21","first-page":"3671","article-title":"Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma","volume":"59","author":"Tonkinson","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2005.09.010_bib22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s002800050953","article-title":"Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay","volume":"44","author":"Britten","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl 6","key":"10.1016\/j.clinthera.2005.09.010_bib23","first-page":"55","article-title":"MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma","volume":"26","author":"Teicher","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib24","first-page":"1016","article-title":"Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts","volume":"6","author":"Teicher","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2005.09.010_bib25","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/bjc.1995.178","article-title":"Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines","volume":"71","author":"Jackman","year":"1995","journal-title":"Br J Cancer"},{"issue":"Suppl 6","key":"10.1016\/j.clinthera.2005.09.010_bib26","first-page":"68","article-title":"Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs","volume":"26","author":"Schultz","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib27","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1158\/0008-5472.CAN-03-3953","article-title":"Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: Association with the presence of a secondary transport pathway","volume":"64","author":"Zhao","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2005.09.010_bib28","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V89.3.1013","article-title":"Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression","volume":"89","author":"Gorlick","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2005.09.010_bib29","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/jnci\/92.16.1295","article-title":"A family of drug transporters: The multidrug resistance-associated proteins","volume":"92","author":"Borst","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clinthera.2005.09.010_bib30","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0006-2952(03)00007-8","article-title":"Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line","volume":"65","author":"Wang","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib31","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s002800051000","article-title":"Glutamyl hydrolase and the multitargeted antifolate LY231514","volume":"44","author":"Rhee","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib32","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1158\/0008-5472.CAN-04-2810","article-title":"The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates","volume":"65","author":"Wielinga","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2005.09.010_bib33","first-page":"3235","article-title":"Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514","volume":"18","author":"Worzalla","year":"1998","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clinthera.2005.09.010_bib34","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1200\/JCO.1995.13.11.2842","article-title":"Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation","volume":"13","author":"Rinaldi","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib35","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s002800050992","article-title":"A phase I evaluation of multitargeted antifolate (MTA, LY231514) administered every 21 days, utilizing the modified continual reassessment method for dose escalation","volume":"44","author":"Rinaldi","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib36","first-page":"605","article-title":"A phase I and pharmacokinetic study of Ly231514, the multitargeted antifolate","volume":"4","author":"McDonald","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2005.09.010_bib37","series-title":"1998 ASCO Annual Meeting, Abstract 900","article-title":"Comparative human pharmacokinetics of MTA in three phase I studies","author":"Sharma","year":"1998"},{"key":"10.1016\/j.clinthera.2005.09.010_bib38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s002800000144","article-title":"Population pharmacokinetics of pemetrexed disodium (Alimta) in patients with cancer","volume":"46","author":"Ouellet","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib39","series-title":"2001 ASCO Annual Meeting, Abstract 368","article-title":"Phase I and pharmacokinetic study of pemetrexed disiodium (LY231514, MTA, Alimta) in patients (pts) with impaired renal function","author":"Takimoto","year":"2001"},{"key":"10.1016\/j.clinthera.2005.09.010_bib40","first-page":"158","article-title":"A phase I dose-finding study of pemetrexed supplemented with folic acid (FA) and vitamin B12 in Japanese patients with solid tumors","volume":"22","author":"Nakagawa","year":"2003"},{"key":"10.1016\/j.clinthera.2005.09.010_bib41","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/106002809202600219","article-title":"Methotrexate and nonsteroidal antiinflammatory drug interactions","volume":"26","author":"Frenia","year":"1992","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2005.09.010_bib42","first-page":"2072","article-title":"The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: Impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg","volume":"22","author":"Kremer","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib43","first-page":"1274","article-title":"Low dose MTX and NSAID induced \u201cmild\u201d renal insufficiency and severe neutropenia","volume":"18","author":"Kraus","year":"1991","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib45","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.1999.17.10.3009","article-title":"Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin","volume":"17","author":"Thodtmann","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib46","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/annonc\/mdh279","article-title":"Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors","volume":"15","author":"Misset","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib47","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2000.18.8.1748","article-title":"Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors","volume":"18","author":"Adjei","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib48","author":"Thodtmann"},{"key":"10.1016\/j.clinthera.2005.09.010_bib49","author":"Millward"},{"key":"10.1016\/j.clinthera.2005.09.010_bib50","author":"Mackay"},{"key":"10.1016\/j.clinthera.2005.09.010_bib51","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1200\/JCO.2002.10.073","article-title":"Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma","volume":"20","author":"Hughes","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib52","author":"Schwartz"},{"key":"10.1016\/j.clinthera.2005.09.010_bib53","first-page":"40","article-title":"Pemetrexed and cyclophosphamide in patients with locally advanced or metastatic breast cancer: A phase I study","volume":"22","author":"Dittrich","year":"2003"},{"key":"10.1016\/j.clinthera.2005.09.010_bib54","author":"Johnson"},{"key":"10.1016\/j.clinthera.2005.09.010_bib55","first-page":"363","article-title":"Pemetrexed and irinotecan as second-line therapy for locally advanced or metastatic colorectal cancer: A phase I dose escalation study","volume":"22","author":"Kroening","year":"2003"},{"key":"10.1016\/j.clinthera.2005.09.010_bib56","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.14_suppl.2103","article-title":"Phase I study of pemetrexed plus paclitaxel in patients with solid tumor","volume":"22","author":"Graefe","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib57","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.14_suppl.2053","article-title":"Phase I trial of pemetrexed plus paclitaxel administered every 21 days in patients with advanced solid tumors","volume":"22","author":"Awada","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib58","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.14_suppl.2141","article-title":"A phase I clinical study of biweekly pemetrexed and gemcitabine in patients with advanced solid tumors","volume":"22","author":"Dudek","year":"2004","journal-title":"J Clin Oncol"},{"issue":"Suppl 6","key":"10.1016\/j.clinthera.2005.09.010_bib59","first-page":"94","article-title":"A phase I trial of MTA and gemictabine in patients with locally advanced or metastatic cancer","volume":"26","author":"Adjei","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib60","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1023\/A:1023983327622","article-title":"Pemetrexed (Alimta) and epirubicin in patients with locally advanced or metastatic breast cancer: A phase I study","volume":"79","author":"Paridaens","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clinthera.2005.09.010_bib61","doi-asserted-by":"crossref","first-page":"14s","DOI":"10.1200\/jco.2004.22.14_suppl.3096","article-title":"Pemetrexed\/gemcitabine\/cisplatin: Phase I trial in patients with solid tumors","volume":"22","author":"Bolling","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib62","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1200\/JCO.2003.06.122","article-title":"Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma","volume":"21","author":"Scagliotti","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib63","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cis-platin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib64","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.14_suppl.7053","article-title":"A phase 2 clinical trial of pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural mesothelioma (MPM)","volume":"22","author":"Janne","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib65","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib66","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.14_suppl.7074","article-title":"A phase II trial of pemetrexed (P) plus carboplatin (C) in patients (pts) with advanced non-small-cell lung cancer (NSCLC)","volume":"22","author":"Koshy","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib67","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1158\/1078-0432.CCR-04-0218","article-title":"Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer","volume":"10","author":"Monnerat","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2005.09.010_bib68","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.14_suppl.7130","article-title":"Pemetrexed plus gemcitabine as front-line therapy for patients with advanced stage non-small cell lung cancer","volume":"22","author":"Treat","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib69","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.14_suppl.7070","article-title":"Pemetrexed(Pem)\/gemcitabine (Gem) as front-line therapy for advanced NSCLC: A randomized, phase II trial of three schedules","volume":"22","author":"Adjei","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib70","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.14_suppl.7204","article-title":"Randomized phase II trial of pemetrexed with either cisplatin or carboplatin in extensive stage small cell lung cancer","volume":"22","author":"Socinski","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib71","author":"Mennel"},{"key":"10.1016\/j.clinthera.2005.09.010_bib72","author":"Gomez"},{"key":"10.1016\/j.clinthera.2005.09.010_bib73","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.14_suppl.639","article-title":"A phase II study of a combination of pemetrexed (Pem) and gemcitabine (Gem) in patients with metastatic breast cancer (MBC): An NCCTG study","volume":"22","author":"Ma","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib74","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/annonc\/mdg406","article-title":"Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer","volume":"14","author":"Bajetta","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib75","first-page":"276","article-title":"Pemetrexed and oxaliplatin for first-line treatment of patients with advanced colorectal cancer: A phase II trial of the NSABP foundation research program","volume":"22","author":"Atkins","year":"2003"},{"key":"10.1016\/j.clinthera.2005.09.010_bib76","author":"Kindler"},{"key":"10.1016\/j.clinthera.2005.09.010_bib77","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.14_suppl.4007","article-title":"A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer","volume":"22","author":"Richards","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib78","first-page":"411","article-title":"Phase II study of pemetrexed (PEM) for second-line treatment of transitional cell cancer (TCC) of the bladder","volume":"22","author":"Sweeney","year":"2003"},{"key":"10.1016\/j.clinthera.2005.09.010_bib79","series-title":"Chemotherapy Foundation Symposium XXI Innovative Cancer Therapy for Tomorrow","article-title":"Alimta (pemetrexed) for relapsed bladder cancer","author":"Sweeney","year":"2003"},{"key":"10.1016\/j.clinthera.2005.09.010_bib80","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2005.09.010_bib81","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00944177","article-title":"Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria","volume":"10","author":"Green","year":"1992","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clinthera.2005.09.010_bib82","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 18","key":"10.1016\/j.clinthera.2005.09.010_bib83","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/sonc.2002.37469","article-title":"Emerging insights into the biology and therapy of malignant mesothelioma","volume":"29","author":"Vogelzang","year":"2002","journal-title":"Semin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.09.010_bib84","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/j.lungcan.2004.04.020","article-title":"Chemotherapy for malignant pleural mesothelioma: Past results and recent developments","volume":"45","author":"Tomek","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clinthera.2005.09.010_bib85","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1378\/chest.108.4.1122","article-title":"A proposed new international TNM staging system for malignant mesothelioma","volume":"108","author":"Rusch","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2005.09.010_bib86","author":"Shin"},{"key":"10.1016\/j.clinthera.2005.09.010_bib87","first-page":"545","article-title":"Homocysteine and methylmalonic acid: Markers to predict and avoid toxicity from pemetrexed therapy","volume":"1","author":"Niyikiza","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clinthera.2005.09.010_bib88","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S0959-8049(01)00117-4","article-title":"A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer","volume":"37","author":"Miles","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinthera.2005.09.010_bib89","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1023\/A:1008305205159","article-title":"Phase II study of the multitargeted antifolate LY231514 (Alimta, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer","volume":"11","author":"Miller","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib90","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1158\/1078-0432.CCR-03-0520","article-title":"Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines","volume":"10","author":"Giovannetti","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2005.09.010_bib91","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1200\/JCO.1992.10.6.896","article-title":"Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate","volume":"10","author":"Advanced Colorectal Cancer Meta-Analysis Project","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib92","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1634\/theoncologist.9-5-482","article-title":"FDA drug approval summaries: Pemetrexed (Alimta)","volume":"9","author":"Hazarika","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.clinthera.2005.09.010_bib93","first-page":"621","article-title":"Improving quality of life in patients with malignant pleural mesothelioma: Results of the randomized pemetrexed + cisplatin vs. cisplatin trial using the LCSS-Meso instrument","volume":"22","author":"Gralla","year":"2003"},{"key":"10.1016\/j.clinthera.2005.09.010_bib94","first-page":"647","article-title":"Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed + cisplatin vs. cisplatin in malignant pleural mesothelioma","volume":"22","author":"Symanowski","year":"2003"},{"key":"10.1016\/j.clinthera.2005.09.010_bib95","first-page":"667","article-title":"Secondary (post-study) chemotherapy in the phase III study of pemetrexed + cisplatin vs. cisplatin in malignant pleural mesothelioma is associated with longer survival","volume":"22","author":"Manegold","year":"2003"},{"key":"10.1016\/j.clinthera.2005.09.010_bib96","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.14_suppl.8125","article-title":"Determining the frequency of quality of life (QL) assessment in chemotherapy treatment: Using the LCSS-Meso in the randomized pemetrexed + cisplatin trial in 448 patients with mesothelioma (MPM) as an example","volume":"22","author":"Hollen","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib97","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.14_suppl.7195","article-title":"Pemetrexed alone or in combination with cisplatin in previously treated patients with malignant pleural mesothelioma (MPM): Outcomes of an expanded access program (EAP)","volume":"22","author":"Orlando","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib98","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.14_suppl.7192","article-title":"Pemetrexed in combination with cisplatin in the treatment of chemonaive patients with malignant pleural mesothelioma (MPM): Outcomes on expanded access program (EAP)","volume":"22","author":"Wozniak","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib99","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.14_suppl.7198","article-title":"Pemetrexed alone or in combination with cisplatin in the treatment of patients with peritoneal mesothelioma (PM): Outcomes of an expanded access program (EAP) in patients with malignant mesothelioma (MM)","volume":"22","author":"Bloss","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib100","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1093\/ndt\/12.12.2478","article-title":"Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application","volume":"12","author":"Kuhlmann","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clinthera.2005.09.010_bib101","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/sonc.2002.30232","article-title":"The role of gemcitabine in the treatment of malignant mesothelioma","volume":"29","author":"Kindler","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib102","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0169-5002(00)00166-5","article-title":"Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B","volume":"31","author":"Kindler","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clinthera.2005.09.010_bib103","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11864-000-0046-5","article-title":"Peritoneal mesothelioma","volume":"1","author":"Taub","year":"2000","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib104","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.14_suppl.7201","article-title":"Pemetrexed + cisplatin (DDP) in patients with malignant peritoneal mesothelioma (AbM)","volume":"22","author":"Karthaus","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib105","first-page":"833","article-title":"Treatment of head and neck and esophageal xenografts employing Alimta and concurrent ionizing radiation","volume":"19","author":"Mauceri","year":"2001","journal-title":"Int J Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2005.09.010_bib106","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1016\/j.lungcan.2004.07.972","article-title":"Chemotherapy in stage-IV NSCLC","volume":"45","author":"Reck","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clinthera.2005.09.010_bib107","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11864-005-0016-z","article-title":"Antimetabolites in the management of non-small cell lung cancer","volume":"6","author":"Budde","year":"2005","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib108","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2005.09.010_bib109","doi-asserted-by":"crossref","first-page":"4210S","DOI":"10.1158\/1078-0432.CCR-040009","article-title":"Cytotoxic chemotherapy in advanced non-small cell lung cancer: A review of standard treatment paradigms","volume":"10","author":"Socinski","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2005.09.010_bib110","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib111","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","article-title":"Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens [published correction appears in J Clin Oncol. 2004;22:209]","volume":"18","author":"Fossella","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib112","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/annonc\/mdf115","article-title":"Phase II trial of pemetrexed disodium (Alimta, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer","volume":"13","author":"Clarke","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib113","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1200\/JCO.1999.17.4.1194","article-title":"Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study","volume":"17","author":"Rusthoven","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib114","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/bmj.311.7010.889","article-title":"Chemotherapy for non-small cell lung cancer","volume":"311","author":"Carbone","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2005.09.010_bib115","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/1097-0142(20010801)92:3<595::AID-CNCR1359>3.0.CO;2-D","article-title":"Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: A study of the National Cancer Institute of Canada Clinical Trials Group","volume":"92","author":"Shepherd","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2005.09.010_bib116","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1023\/A:1008336931378","article-title":"Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, Alimta) and cisplatin: A multicenter phase II trial","volume":"11","author":"Manegold","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib117","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.bjc.6600540","article-title":"Platinum drugs in the treatment of non-small-cell lung cancer","volume":"87","author":"Cosaert","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2005.09.010_bib118","first-page":"625","article-title":"Phase II randomized study of pemetrexed + carboplatin or oxaliplatin, as front-line chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer","volume":"22","author":"Scagliotti","year":"2003"},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2005.09.010_bib119","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/S0169-5002(01)00395-6","article-title":"Gemcitabine and pemetrexed disodium combinations in vitro and in vivo","volume":"34","author":"Adjei","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clinthera.2005.09.010_bib120","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1586\/14737140.4.3.345","article-title":"Gemcitabine (Gemzar) in non-small cell lung cancer","volume":"4","author":"Manegold","year":"2004","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clinthera.2005.09.010_bib121","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1200\/JCO.1997.15.2.744","article-title":"Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small-cell lung cancer","volume":"15","author":"Abratt","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib122","first-page":"233","article-title":"In vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines","volume":"8","author":"Tesei","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2005.09.010_bib123","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/annonc\/mdg099","article-title":"Alimta (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: A phase II study","volume":"14","author":"Smit","year":"2003","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.09.010_bib124","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S0959-8049(05)80262-X","article-title":"Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS)","volume":"29A","author":"Hollen","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinthera.2005.09.010_bib125","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.14_suppl.7035","article-title":"Does second-line therapy for non-small cell lung cancer (NSCLC) result in symptom palliation? Analysis of 484 patients from a randomized trial of pemetrexed vs docetaxel","volume":"22","author":"De Marinis","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib126","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.14_suppl.7131","article-title":"Pemetrexed vs docetaxel for non-small cell lung cancer (NSCLC): Could vitamin supplementation affect docetaxel survival? An exploratory analysis","volume":"22","author":"Fossella","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib127","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.14_suppl.7135","article-title":"Post study docetaxel in non-small cell lung cancer (NSCLC) patients after discontinuation from a randomized phase III trial of pemetrexed versus docetaxel: An exploratory analysis","volume":"22","author":"Pujol","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib128","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJM199810013391407","article-title":"Treatment of breast cancer","volume":"339","author":"Hortobagyi","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2005.09.010_bib129","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/jama.273.7.542","article-title":"Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results","volume":"273","author":"Bonadonna","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2005.09.010_bib130","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1093\/annonc\/mdg339","article-title":"Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines","volume":"14","author":"Martin","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib131","first-page":"122","article-title":"A phase II trial of pemetrexed disodium (Alimta, LY231514) in metastatic breast cancer (MBC) patients who have failed anthracyclines (A) and taxanes (T) (salvage chemotherapy)","volume":"64","author":"Llombart-Cussac","year":"2000","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clinthera.2005.09.010_bib132","doi-asserted-by":"crossref","first-page":"146S","DOI":"10.1002\/j.1875-9114.1997.tb03817.x","article-title":"An overview of cyclophosphamide and ifosfamide pharmacology","volume":"17","author":"Fleming","year":"1997","journal-title":"Pharmacotherapy"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2005.09.010_bib133","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.3816\/CBC.2000.s.007","article-title":"Rationale and use of epirubicin-based therapy in the adjuvant setting","volume":"1","author":"Mouridsen","year":"2000","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clinthera.2005.09.010_bib134","first-page":"121","article-title":"AJCC Cancer Staging Manual","author":"American Joint Committee on Cancer","year":"1997"},{"key":"10.1016\/j.clinthera.2005.09.010_bib135","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib136","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1444-0903.2004.00658.x","article-title":"Modern management of pancreatic carcinoma","volume":"34","author":"Goldstein","year":"2004","journal-title":"Intern Med J"},{"key":"10.1016\/j.clinthera.2005.09.010_bib137","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.2002.11.149","article-title":"Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297","volume":"20","author":"Berlin","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib138","series-title":"Presented at the 40th Annual Meeting of the American Society of Clinical Oncology","article-title":"A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer","author":"Richards","year":"2004"},{"key":"10.1016\/j.clinthera.2005.09.010_bib139","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","article-title":"A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer","volume":"22","author":"Goldberg","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib140","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/(SICI)1097-0142(20000415)88:8<1807::AID-CNCR8>3.0.CO;2-L","article-title":"Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: Results from a phase II study","volume":"88","author":"John","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2005.09.010_bib141","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1023\/A:1008372529239","article-title":"Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study","volume":"10","author":"Cripps","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib142","author":"Paulson"},{"key":"10.1016\/j.clinthera.2005.09.010_bib143","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer","volume":"343","author":"Saltz","year":"2000","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2005.09.010_bib144","doi-asserted-by":"crossref","first-page":"ii31","DOI":"10.1093\/annonc\/mdg726","article-title":"Gastric cancer: Epidemiology, pathology and treatment","volume":"14","author":"Alberts","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib145","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1200\/JCO.2000.18.14.2648","article-title":"Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Co-operative Group","volume":"18","author":"Vanhoefer","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib146","series-title":"Manual for Staging Cancer","author":"American Joint Committee on Cancer","year":"1987"},{"key":"10.1016\/j.clinthera.2005.09.010_bib147","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","article-title":"A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin with metastatic urothelial carcinoma: A cooperative group study [published correction appears in J Clin Oncol. 1993;11:384]","volume":"10","author":"Loehrer","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib148","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.1990.8.6.1050","article-title":"A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors","volume":"8","author":"Logothetis","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib149","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Masse","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib150","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1200\/JCO.2001.19.12.3018","article-title":"Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: A phase II trial of the Minnie Pearl Cancer Research Network","volume":"19","author":"Meluch","year":"2001","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2005.09.010_bib151","first-page":"61","article-title":"Significant activity of the multitargeted antifolate MTA (LY231514) in advanced transitional cell carcinoma (TCC) of the bladder: Results of a phase II trial","volume":"9","author":"Paz-Ares","year":"1998","journal-title":"Ann Oncol"},{"issue":"Suppl 8","key":"10.1016\/j.clinthera.2005.09.010_bib152","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1002\/cncr.11279","article-title":"Review of a promising new agent\u2014pemetrexed disodium","volume":"97","author":"Paz-Ares","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2005.09.010_bib153","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0959-8049(98)00030-6","article-title":"A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum","volume":"34","author":"Lorusso","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinthera.2005.09.010_bib154","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1023\/A:1025480914273","article-title":"A phase II trial of pemetrexed in patients with metastatic renal cancer","volume":"21","author":"Thodtmann","year":"2003","journal-title":"Invest New Drugs"},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2005.09.010_bib155","first-page":"339a","article-title":"MTA (LY231514) in advanced carcinoma of the cervix","volume":"9","author":"Goedals","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib156","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0020-7292(00)90001-8","article-title":"FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers","volume":"70","author":"Benedet","year":"2000","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.clinthera.2005.09.010_bib157","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1053\/j.seminoncol.2004.09.014","article-title":"Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck","volume":"31","author":"Fanucchi","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clinthera.2005.09.010_bib158","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1054\/bjoc.2001.2010","article-title":"Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck","volume":"85","author":"Pivot","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2005.09.010_bib159","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1006\/mgme.1999.2813","article-title":"Folate-homocysteine interrelations: Potential new markers of folate status","volume":"67","author":"Lucock","year":"1999","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.clinthera.2005.09.010_bib160","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0002-9343(94)90149-X","article-title":"Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies","volume":"96","author":"Savage","year":"1994","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2005.09.010_bib161","author":"Bunn"},{"key":"10.1016\/j.clinthera.2005.09.010_bib162","first-page":"411","article-title":"Phase I and pharmacokinetic (PK) study of the multitargeted antifolate (MTA) LY231514 with folic acid","volume":"22","author":"Hammond","year":"2003"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929180500175X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929180500175X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T16:58:18Z","timestamp":1706720298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929180500175X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":159,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["S014929180500175X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2005.09.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}